Xenon Pharmaceuticals Inc 10-Q for FY2026 Q3
Xenon Pharmaceuticals Inc. (XENE)
10-Q
2026-11-09
For: 2026-09-30
View Original
Added on
November 09, 2026
About this 10-Q
Xenon Pharmaceuticals Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Xenon Pharmaceuticals Inc. submitted azetukalner’s NDA for focal seizures to the U.S. Food & Drug Administration in September 2026. Net loss was $323.5 million for the nine months ended September 30, 2026, while cash and marketable securities totaled $1,153.5 million. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $0
- compared with $0 a year earlier
- Net loss
- $110.44M
- compared with a net loss of $90.9M a year earlier
- Diluted EPS
- -$1.11
- compared with -$1.15 a year earlier